Financial Comparison: Cartesian Therapeutics (RNAC) and Its Peers

Cartesian Therapeutics (NASDAQ:RNAC) is one of 1,061 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its peers? We will compare Cartesian Therapeutics to similar companies based on the strength of its analyst recommendations, dividends, earnings, valuation, institutional ownership, profitability and risk.

Profitability

This table compares Cartesian Therapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cartesian Therapeutics	-510.72%	N/A	-6.03%
Cartesian Therapeutics Competitors	-3,590.11%	-276.96%	-39.10%

Earnings and Valuation

This table compares Cartesian Therapeutics and its peers top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Cartesian Therapeutics	$47.94 million	-$219.71 million	-0.33
Cartesian Therapeutics Competitors	$9.59 billion	$147.39 million	-5.62

Cartesian Therapeutics’ peers have higher revenue and earnings than Cartesian Therapeutics. Cartesian Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Insider and Institutional Ownership

86.9% of Cartesian Therapeutics shares are held by institutional investors. Comparatively, 44.1% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 57.9% of Cartesian Therapeutics shares are held by insiders. Comparatively, 13.7% of shares of all “Pharmaceutical preparations” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Cartesian Therapeutics and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cartesian Therapeutics	0	2	8	0	2.80
Cartesian Therapeutics Competitors	7858	21320	48962	1245	2.55

Cartesian Therapeutics presently has a consensus target price of $42.86, suggesting a potential upside of 143.09%. As a group, “Pharmaceutical preparations” companies have a potential upside of 188.57%. Given Cartesian Therapeutics’ peers higher possible upside, analysts plainly believe Cartesian Therapeutics has less favorable growth aspects than its peers.

Risk & Volatility

Cartesian Therapeutics has a beta of 0.56, suggesting that its stock price is 44% less volatile than the S&P 500. Comparatively, Cartesian Therapeutics’ peers have a beta of 3.65, suggesting that their average stock price is 265% more volatile than the S&P 500.

Summary

Cartesian Therapeutics beats its peers on 8 of the 13 factors compared.

About Cartesian Therapeutics

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.